Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1).
Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1.
Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1.
Location: France, Grand Est, Reims
Employees: 1-10
Founded date: 2019
Investors 1
| Date | Name | Website |
| 07.01.2022 | Capital Gr... | capitalgra... |
Mentions in press and media 1
| Date | Title | Description |
| - | Apmonia Therapeutics | “New ways of helping patients fight cancer DISCOVER OUR STORY About us Apmonia Therapeutics is a biotech company committed to develop therapeutic strategies towards multiple types of cancer. We are developing a first-in-class pipeline of ne... |